| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
|
| loss of function
|
|
in gastric cancers advanced stage by deletion or hypermethylation of the promoter or by protein mislocalization and in bile duct and pancreatic carcinoma |
| tumoral
|
|
| --over
|
|
|
in primary and metastatic pancreatic ductal adenocarcinoma |
| tumoral
|
|
| --low
|
|
|
by promoter hypermethylation of the CpG island in colorectal cancer |
| tumoral
|
| deletion
|
|
|
|
in hepatocellular carcinoma |
| tumoral
|
|
|
| loss of function
|
|
by hypermethylation in hepatocellular carcinoma |
| tumoral
|
|
|
| loss of function
|
|
inactivated by aberrant DNA methylation in 73p 100 of primary bladder tumor specimens and 86 p100 (six of seven) of bladder tumor cell lines |
| tumoral
|
|
| --over
|
|
|
in basal cell carcinomas |
| tumoral
|
|
| --low
|
|
in response to hypoxia suppressing RUNX3 (through histone methylation and deacetylation through G9a HMT and HDAC1) in gastric cancer cells at the transcriptional level  |
| tumoral
|
|
| --low
|
|
|
epigenetic silencing of RUNX3 gene expression by promoter hypermethylation may play an important role in esophageal squamous cell carcinoma development |
| tumoral
|
|
| --over
|
|
|
promoted cell growth and inhibited apoptosis in head and neck cancer cells ( |
| tumoral
|
|
|
| loss of function
|
|
loss of RUNX3 expression can enhance the AKT1-mediated signaling pathway and promote the tumorigenesis process in human gastric cancer ( |
| constitutional
|
|
| --other
|
|
|
aberrant expression of RUNX3 was associated with the pathogenesis of Immune thrombocytopenia (ITP) |
